Find, compare & contact
Grazoprevir
API Manufacturers & Suppliers
Belgium
United States
India
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Grazoprevir API 1350514-68-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Grazoprevir. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Grazoprevir
- Cas Number:
- 1350514-68-9
- DrugBank number:
- DB11575
- Unique Ingredient Identifier:
- 8YE81R1X1J
About Grazoprevir
So, what does it do? Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients Treatment options for chronic Hepatitis C have advanced significantly since 20 with the development of Direct Acting Antivirals (DAAs) such as Grazoprevir. Grazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 Synthesis. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS3, NS4A, NS4B, NS5A and NS5B.
The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Grazoprevir is still effective against HCV particularly when paired with Elbasvir.
You can ask the supplier for more technical information about the product.
Grazoprevir is a type of Other Antiretrovirals
The category of Other Antiretrovirals falls under the broad umbrella of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the treatment of retroviral infections, including HIV. Other Antiretrovirals encompass a range of compounds that target various stages of the retroviral life cycle and provide alternative therapeutic options.
These APIs exhibit potent antiretroviral activity and are designed to combat drug-resistant strains of the virus, enhancing treatment efficacy. They work by inhibiting key enzymes involved in viral replication or by blocking viral entry into host cells.
One notable subcategory within Other Antiretrovirals is fusion inhibitors. These APIs prevent the fusion of the viral envelope with the host cell membrane, thereby inhibiting viral entry and subsequent infection. They target the viral protein gp41, which is crucial for fusion.
Another subcategory is integrase inhibitors, which hinder the action of the viral enzyme integrase. By doing so, they prevent the integration of viral DNA into the host cell genome, thus impeding viral replication and propagation.
Additionally, maturation inhibitors are included in this subcategory. These APIs interfere with the final stages of viral assembly and maturation, disrupting the production of infectious viral particles.
By expanding the repertoire of available antiretroviral options, Other Antiretrovirals play a vital role in the management of retroviral infections, especially when other treatment regimens have failed or become ineffective. Their development and utilization contribute to the advancement of HIV therapy and ultimately improve patient outcomes.
Grazoprevir (Other Antiretrovirals), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
